Scott M. Rocklage Ph.D. is a businessman, scientist, entrepreneur and investor. He has accumulated decades of experience in a variety of fields ranging from pharmaceuticals to business. Rocklage first joined the 5AM Ventures team in 2003 as a Venture Partner. After a year of success, he decided to rejoin as a Managing Partner, offering him more responsibility and control.
The 5AM Venture team has seen many accomplishments under the guidance and efforts of Scott Rocklage. His years of experience and expertise have been manifested through the growth of the company itself. Read more: Scott Racklage | Bloomberg
Before investing time in business and pharmaceuticals, Scott Rocklage attended the University of California, Berkley where he received his Bachelors of Science in Chemistry. This degree eventually led to the attendance of the prestigious Massachusetts Institute of Technology where Scott completed his Ph.D. in Chemistry.
It was this extensive education that propelled Rocklage into the world of pharmaceuticals. In addition to his educational accomplishments, Rocklage also has been awarded with approval of the Food and Drug Administration for several drugs he has helped to develop.
Scott Rocklage has also written over 100 peer-reviewed publications through which he addresses several subjects within chemistry and pharmaceuticals. He has also been the co-inventor or inventor regarding 30 United States patents. At MIT, Rocklage conducted research in the laboratory of the Nobel Prize in Chemistry in 2005 winner Richard R. Schrock.
Beyond 5AM ventures, Rocklage has over three decades of experience in healthcare management. Rocklage’s extensive experience has seen his election on the board of several well-known companies. He currently serves as the Chairman for Kinestral, Rennovia and Cidara.
He serves on the board for Pulmatrix and Epirus currently. In the past, Rocklage served as President and CEO of Nycomed Salutar as well as CEO and Chairman for Cubist Pharmaceuticals. Under Rocklage’s guidance and leadership, three U.S. New Drug Applications were approved by the FDA. The three drugs include Cubicin®, Omniscan™ and Teslascan®.
Due to his considerable contributions to pharmaceutical development and research, many companies seek Rocklage for top positions on their boards. His guidance and expertise have led to the ongoing success of many companies.